TY  - GEN
A1  - Tschorn, Mira
A1  - Kuhlmann, Stella Linnea
A1  - Rieckmann, Nina
A1  - Beer, Katja
A1  - Grosse, Laura
A1  - Arolt, Volker
A1  - Waltenberger, Johannes
A1  - Haverkamp, Wilhelm
A1  - Müller-Nordhorn, Jacqueline
A1  - Hellweg, Rainer
A1  - Ströhle, Andreas
T1  - Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease
T2  - Zweitveröffentlichungen der Universität Potsdam : Humanwissenschaftliche Reihe
N2  - Objective:
Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). 

Methods: 
The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. 

Results: 
Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. 

Conclusion: 
Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.
T3  - Zweitveröffentlichungen der Universität Potsdam : Humanwissenschaftliche Reihe - 850 
KW  - depression
KW  - BDNF
KW  - coronary heart disease
KW  - heart failure
KW  - somatic comorbidity
KW  - acute coronary syndrome
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-557315
SN  - 1866-8364
IS  - 1
ER  - 
TY  - GEN
A1  - Rauch, Bernhard
A1  - Davos, Constantinos H.
A1  - Doherty, Patrick
A1  - Saure, Daniel
A1  - Metzendorf, Maria-Inti
A1  - Salzwedel, Annett
A1  - Völler, Heinz
A1  - Jensen, Katrin
A1  - Schmid, Jean-Paul
T1  - The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy
BT  - a systematic review and meta-analysis of randomized and non-randomized studies - the Cardiac Rehabilitation Outcome Study (CROS)
T2  - Postprints der Universität Potsdam : Humanwissenschaftliche Reihe
N2  - Background The prognostic effect of multi-component cardiac rehabilitation (CR) in the modern era of statins and acute revascularisation remains controversial. Focusing on actual clinical practice, the aim was to evaluate the effect of CR on total mortality and other clinical endpoints after an acute coronary event.

Design Structured review and meta-analysis.

Methods Randomised controlled trials (RCTs), retrospective controlled cohort studies (rCCSs) and prospective controlled cohort studies (pCCSs) evaluating patients after acute coronary syndrome (ACS), coronary artery bypass grafting (CABG) or mixed populations with coronary artery disease (CAD) were included, provided the index event was in 1995 or later.

Results Out of n=18,534 abstracts, 25 studies were identified for final evaluation (RCT: n=1; pCCS: n=7; rCCS: n=17), including n=219,702 patients (after ACS: n=46,338; after CABG: n=14,583; mixed populations: n=158,781; mean follow-up: 40 months). Heterogeneity in design, biometrical assessment of results and potential confounders was evident. CCSs evaluating ACS patients showed a significantly reduced mortality for CR participants (pCCS: hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.20-0.69; rCCS: HR 0.64, 95% CI 0.49-0.84; odds ratio 0.20, 95% CI 0.08-0.48), but the single RCT fulfilling Cardiac Rehabilitation Outcome Study (CROS) inclusion criteria showed neutral results. CR participation was also associated with reduced mortality after CABG (rCCS: HR 0.62, 95% CI 0.54-0.70) and in mixed CAD populations.

Conclusions CR participation after ACS and CABG is associated with reduced mortality even in the modern era of CAD treatment. However, the heterogeneity of study designs and CR programmes highlights the need for defining internationally accepted standards in CR delivery and scientific evaluation.
T3  - Zweitveröffentlichungen der Universität Potsdam : Humanwissenschaftliche Reihe - 418 
KW  - rehabilitation
KW  - acute coronary syndrome
KW  - coronary bypass grafting
KW  - coronary artery disease
KW  - mortality
KW  - hospital readmission
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-405346
IS  - 418
ER  -